Investing
Proceeds From Sale And Maturity Of Available For Sale Securities
Vertex Pharmaceuticals Proceeds From Sale And Maturity Of Available For Sale Securities increased by 102.3% to $2.21B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 34.9%, from $1.64B to $2.21B. Over 3 years (FY 2021 to FY 2025), Proceeds From Sale And Maturity Of Available For Sale Securities shows an upward trend with a 127.7% CAGR.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
High proceeds indicate active portfolio rebalancing or the liquidation of assets to meet liquidity needs.
Detailed definition
This represents the cash inflows resulting from the sale, redemption, or maturity of investment securities classified as...
Peer comparison
Standard for insurance companies; reflects the liquidity and turnover of the investment asset base.
Metric ID:
investing_proceeds_from_sale_and_maturity_of_available_f_0efd08Historical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $124.83M | $124.83M | $124.83M | $484.10M | $50.00M | $239.80M | $331.20M | $218.10M | $710.50M | $1.18B | $1.11B | $1.46B | $1.64B | $1.84B | $1.33B | $1.09B | $2.21B |
| QoQ Change | — | +0.0% | +0.0% | +287.8% | -89.7% | +379.6% | +38.1% | -34.1% | +225.8% | +66.4% | -5.9% | +31.3% | +12.1% | +12.3% | -27.7% | -17.9% | +102.3% |
| YoY Change | — | — | — | +287.8% | — | — | — | -54.9% | >999% | +393.2% | +235.8% | +569.5% | +130.5% | +55.5% | +19.5% | -25.2% | +34.9% |
Range$50.00M – $2.21B
CAGR+105.1%
Avg YoY Growth+269.8%
Median YoY Growth+130.5%
Proceeds From Sale And Maturity Of Available For Sale Securities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
- Vertex Pharmaceuticals (VRTX) reported proceeds from sale and maturity of available for sale securities of $2.21B in Q1 2026.
- How has Vertex Pharmaceuticals's proceeds from sale and maturity of available for sale securities changed year-over-year?
- Vertex Pharmaceuticals's proceeds from sale and maturity of available for sale securities increased by 34.9% year-over-year, from $1.64B to $2.21B.
- What is the long-term trend for Vertex Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's proceeds from sale and maturity of available for sale securities has grown at a 127.7% compound annual growth rate (CAGR), from $499.30M to $5.90B.
- What does proceeds from sale and maturity of available for sale securities mean?
- Cash received from selling or maturing investment securities.